OncoMatch/Clinical Trials/NCT07030712
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Is NCT07030712 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for metastatic neoplasm.
Treatment: MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 — MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Prior therapy
Must have received: standard treatment
have previously failed standard treatment, lack standard treatment options, or are intolerant to standard treatment
Cannot have received: immunotherapy
Exception: except endocrine disorders that can be treated with replacement therapy
Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University ( Site 0101) · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07030712 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify